Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with
8 hours ago
- #trastuzumab deruxtecan
- #metastatic breast cancer
- #endocrine resistance
- Trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) versus physician's choice of chemotherapy (TPC) in HR+, HER2-low/-ultralow metastatic breast cancer (mBC).
- Subgroup analyses showed consistent PFS benefit with T-DXd regardless of time to progression (TTP) on prior first-line endocrine therapy (ET) + CDK4/6 inhibitor (CDK4/6i).
- T-DXd demonstrated superior objective response rate (ORR) and duration of response (DOR) compared to TPC across all subgroups.
- Patients with primary or secondary endocrine resistance and varying disease burdens benefited from T-DXd.
- T-DXd prolonged time until second progression or death (PFS2) compared to TPC in all subgroups.
- Safety profiles of T-DXd and TPC were consistent across subgroups with no new safety signals.
- T-DXd is supported as an effective treatment for HR+, HER2-low/-ultralow mBC post ≥1 ET, irrespective of prior TTP, endocrine resistance, or disease burden.